Abstract Tumor necrosis factor-linked apoptosis-inducing ligand (Path) can be a cytotoxic cytokine that induces most cancers mobile Dying by binding to TRAIL receptors. As a result of its selective cytotoxicity toward cancer cells, TRAIL therapeutics, including recombinant TRAIL and agonistic antibodies focusing on TRAIL receptors, have garnered awareness as promising https://annep429dhk2.law-wiki.com/user